Cypress Capital Group Makes New $189,000 Investment in Kenvue Inc. (NYSE:KVUE)

Cypress Capital Group acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $189,000.

Other large investors have also recently bought and sold shares of the company. Manchester Capital Management LLC grew its position in Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after acquiring an additional 530 shares during the last quarter. Tradition Wealth Management LLC grew its holdings in shares of Kenvue by 2.8% during the fourth quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after purchasing an additional 575 shares during the last quarter. MV Capital Management Inc. raised its holdings in shares of Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after buying an additional 642 shares during the last quarter. Royal Capital Wealth Management LLC lifted its position in Kenvue by 2.3% during the 4th quarter. Royal Capital Wealth Management LLC now owns 29,746 shares of the company’s stock worth $640,000 after buying an additional 673 shares in the last quarter. Finally, Cove Private Wealth LLC grew its holdings in Kenvue by 1.6% during the 2nd quarter. Cove Private Wealth LLC now owns 44,539 shares of the company’s stock worth $810,000 after acquiring an additional 700 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

KVUE stock traded up $0.26 during midday trading on Friday, reaching $21.82. 6,785,642 shares of the company were exchanged, compared to its average volume of 18,865,104. The firm has a market capitalization of $41.78 billion, a price-to-earnings ratio of 27.97, a price-to-earnings-growth ratio of 2.07 and a beta of 1.38. The business has a 50-day moving average price of $19.21 and a two-hundred day moving average price of $19.47. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.10. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The company had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the prior year, the business earned $0.32 earnings per share. The firm’s revenue for the quarter was down .3% on a year-over-year basis. Equities research analysts forecast that Kenvue Inc. will post 1.13 EPS for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.76%. The ex-dividend date is Wednesday, August 14th. This is a boost from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is currently 105.13%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on KVUE shares. UBS Group increased their price objective on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Wednesday, August 7th. HSBC boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. Finally, Citigroup reduced their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.